REGENERON PHARMACEUTICALS, INC. (REGN) Retained Earnings (Accumulated Deficit) USD 2010 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Regeneron Pharmaceuticals, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from 2010 to 2024.
  • Regeneron Pharmaceuticals, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending March 31, 2024 was $28B, a 16% increase year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly Data (USD)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 $28B +$3.86B +16% Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $27.3B +$3.95B +17% Dec 31, 2023 10-Q 2024-05-02
Q3 2023 $26.1B +$3.99B +18.1% Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $25.1B +$4.3B +20.7% Jun 30, 2023 10-Q 2023-08-03
Q1 2023 $24.1B +$4.18B +21% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 $23.3B +$4.34B +22.9% Dec 31, 2022 10-K 2024-02-05
Q3 2022 $22.1B +$5.37B +32.1% Sep 30, 2022 10-Q 2022-11-03
Q2 2022 $20.8B +$5.69B +37.6% Jun 30, 2022 10-Q 2022-08-03
Q1 2022 $19.9B +$7.93B +66.1% Mar 31, 2022 10-Q 2022-05-04
Q4 2021 $19B +$8.08B +74.1% Dec 31, 2021 10-K 2023-02-06
Q3 2021 $16.7B +$7B +71.8% Sep 30, 2021 10-Q 2021-11-04
Q2 2021 $15.1B +$6.21B +69.7% Jun 30, 2021 10-Q 2021-08-05
Q1 2021 $12B +$4B +50% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $10.9B +$3.51B +47.6% Dec 31, 2020 10-K 2022-02-07
Q3 2020 $9.74B +$3.16B +47.9% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $8.9B +$2.98B +50.4% Jun 30, 2020 10-Q 2020-08-05
Q1 2020 $8B +$2.28B +39.8% Mar 31, 2020 10-Q 2020-05-05
Q4 2019 $7.38B +$2.13B +40.5% Dec 31, 2019 10-K 2021-02-08
Q3 2019 $6.59B +$2.15B +48.6% Sep 30, 2019 10-Q 2019-11-05
Q2 2019 $5.92B +$2.08B +54.2% Jun 30, 2019 10-Q 2019-08-06
Q1 2019 $5.73B +$2.44B +74.1% Mar 31, 2019 10-Q 2019-05-07
Q4 2018 $5.25B +$2.31B +78.3% Dec 31, 2018 10-K 2020-02-07
Q3 2018 $4.43B +$1.66B +59.9% Sep 30, 2018 10-Q 2018-11-06
Q2 2018 $3.84B +$1.45B +61% Jun 30, 2018 10-Q 2018-08-02
Q1 2018 $3.29B +$1.29B +64.6% Mar 31, 2018 10-Q 2018-05-03
Q4 2017 $2.95B +$1.2B +68.6% Dec 31, 2017 10-K 2019-02-07
Q3 2017 $2.77B +$1.28B +85.5% Sep 30, 2017 10-Q 2017-11-08
Q2 2017 $2.38B +$1.15B +93.8% Jun 30, 2017 10-Q 2017-08-03
Q1 2017 $2B +$979M +96.1% Mar 31, 2017 10-Q 2017-05-04
Q4 2016 $1.75B +$896M +105% Dec 31, 2016 10-K 2018-02-08
Q3 2016 $1.5B +$797M +114% Sep 30, 2016 10-Q 2016-11-04
Q2 2016 $1.23B +$743M +152% Jun 30, 2016 10-Q 2016-08-04
Q1 2016 $1.02B +$726M +248% Mar 31, 2016 10-Q 2016-05-05
Q4 2015 $853M +$636M +294% Dec 31, 2015 10-K 2017-02-09
Q3 2015 $698M +$553M +380% Sep 30, 2015 10-Q 2015-11-04
Q2 2015 $487M +$422M +644% Jun 30, 2015 10-Q 2015-08-04
Q1 2015 $293M +$320M Mar 31, 2015 10-Q 2015-05-07
Q4 2014 $217M +$309M Dec 31, 2014 10-K 2016-02-11
Q3 2014 $145M +$335M Sep 30, 2014 10-Q 2014-11-04
Q2 2014 $65.5M +$396M Jun 30, 2014 10-Q 2014-08-05
Q1 2014 -$27.2M +$391M +93.5% Mar 31, 2014 10-Q 2014-05-08
Q4 2013 -$92.7M +$424M +82.1% Dec 31, 2013 10-K 2015-02-12
Q3 2013 -$189M +$798M +80.8% Sep 30, 2013 10-Q 2013-11-05
Q2 2013 -$331M +$848M +71.9% Jun 30, 2013 10-Q 2013-08-06
Q1 2013 -$418M +$837M +66.7% Mar 31, 2013 10-Q 2013-05-03
Q4 2012 -$517M +$750M +59.2% Dec 31, 2012 10-K 2014-02-13
Q3 2012 -$987M +$226M +18.7% Sep 30, 2012 10-Q 2012-10-24
Q2 2012 -$1.18B -$27.4M -2.38% Jun 30, 2012 10-Q 2012-07-25
Q1 2012 -$1.26B -$167M -15.3% Mar 31, 2012 10-Q 2012-04-26
Q4 2011 -$1.27B -$222M -21.2% Dec 31, 2011 10-K 2013-02-15
Q3 2011 -$1.21B -$183M -17.7% Sep 30, 2011 10-Q 2011-10-27
Q2 2011 -$1.15B -$154M -15.5% Jun 30, 2011 10-Q 2011-07-28
Q1 2011 -$1.09B Mar 31, 2011 10-Q 2011-05-03
Q4 2010 -$1.05B Dec 31, 2010 10-K 2012-02-21
Q3 2010 -$1.03B Sep 30, 2010 10-Q 2010-10-28
Q2 2010 -$997M Jun 30, 2010 10-Q 2010-07-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.